Dexpramipexole Dihydrochloride

DRUG5 trials

Sponsors

Areteia Therapeutics

Conditions

AsthmaAsthma AttackAsthma; EosinophilicChronic Obstructive Pulmonary DiseaseEosinophilic Asthma

Phase 2

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

Active, not recruitingNCT06533553

Areteia TherapeuticsChronic Obstructive Pulmonary Disease

Start: 2024-07-09End: 2025-12-31Target: 30Updated: 2025-05-14

Phase 3

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Active, not recruitingNCT05748600

Areteia TherapeuticsAsthma Attack, Asthma; Eosinophilic, Eosinophilic Asthma

Start: 2023-01-30End: 2025-12-31Target: 600Updated: 2025-09-05

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

TerminatedNCT05763121

Areteia TherapeuticsAsthma, Asthma; Eosinophilic, Eosinophilic Asthma

Start: 2023-01-30End: 2025-12-08Updated: 2025-12-15

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

TerminatedNCT05813288

Areteia TherapeuticsAsthma, Asthma; Eosinophilic, Eosinophilic Asthma

Start: 2023-03-27End: 2025-12-08Updated: 2025-12-15

Phase III Long-Term Extension Study With Dexpramipexole

TerminatedNCT06388889

Areteia TherapeuticsEosinophilic Asthma

Start: 2024-06-12End: 2025-12-08Updated: 2025-12-15